DISCUSSION
nausea and vomiting
VIRUS
In this phase 2, randomized, placebo-controlled study of the oral antiviral bemnifosbuvir in patients with mild or moderate COVID-19, bemnifosbuvir did not show any meaningful difference in antiviral activity compared with placebo. There were no statistically significant differences between treatment groups in reductions in amount of virus measured by RT-PCR or infectious virus titer across the doses and subgroups analyzed. Bemnifosbuvir was well tolerated at the 550-mg dose; an increase in nausea and vomiting was observed with the 1,100-mg dose.Previous preclinical and phase I studies have predicted that bemnifosbuvir 550 mg twice daily would achieve an effective lung concentration (